Keywords: GLP-1 receptor agonists, obesity, weight loss, non-diabetic patients, cardiovascular outcomes, cost-effectiveness Introduction Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern [7] [8]
Mol Hum Reprod 12(7):421426
This concerns the lower esophageal sphincter and the pyloric sphincter, through which it can be used both prophylactically and as a drug acting directly on reflux symptoms, eliminating its course and symptoms
Further experiments confirmed the presence of vitamin E, quercetin, and cetechin, which demonstrated hepatoprotective effect, and the ROS inhibition was confirmed to be associated with antioxidant activities, thus protecting against ALI
191 Kleber et al